Key facts
- Stellaromics’s last known valuation is $163.0M (Dec 2024).
- It has raised $105.0M; the latest was Early Stage VC ($80.0M) in Dec 2024.
- Notable investors include Stanford University Venture Fund, Bayshore Global Management, Catalyst4, Falcon Creek Capital, Plaisance Capital Management.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Stellaromics
- ·The full record, as it builds
Funding rounds
No funding rounds for Stellaromics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Stellaromics
Developer of gene expression analysis technology designed to study optically extract multi-omic information from biological tissue. The company's tools use patented novel technology for identifying high-resolution three-dimensional transcription patterns in native biological tissue using hydrogel tissue chemistry, allowing researchers to conduct studies on thick tissue samples, and mapping gene expression patterns while preserving the spatial integrity and anatomical structure of the cells.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2022
- Employees
- 49
- Website
- stellaromics.com/
- Ownership
- Privately Held (backing)
Stellaromics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Stellaromics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Stellaromics in its N-PORT filings yet. We sweep new filings monthly.